A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

Inclusion Criteria Patients must have: * Kaposi's sarcoma plus HIV infection OR metastatic solid tumor. * Life expectancy of at least 12 weeks. * NO symptomatic AIDS-defining opportunistic infection within the past 4 weeks. * Recovered from toxicity of any prior anticancer therapy. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Leukemia or lymphoma. * Current gastrointestinal bleeding by stool guaiac. * Extensive bone metastases or significant radiographic osteoporosis in patients with solid tumors. * Active heart disease such as uncontrolled angina, uncompensated congestive heart failure, or dysrhythmias requiring antiarrhythmics. * Acute intercurrent infection other than genital herpes. * Symptomatic or known central nervous system involvement (including brain metastases) unless stable and off therapy. Concurrent Medication: Excluded: * Other anticancer therapy. * Other investigational agents. Patients with the following prior conditions are excluded: * History of acute or chronic gastrointestinal bleeding or inflammatory bowel disease. * History of myocardial infarction within past 6 months. Prior Medication: Excluded: * Anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin C). * Investigational agents within the past 4 weeks.